Company intelligence / Profile preview

Glyscend Therapeutics

Baltimore, Maryland, United Statesglyscend.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Glyscend’s lead candidate GLY-200 has shown significant reductions in postprandial glucose and body weight in patients with type 2 diabetes during completed clinical trials. The drug was well-tolerated with no treatment-related safety signals. A current Phase 2 trial for obesity began dosing patients in June 2024 with results expected Q1 of 2025. The mechanism mimics beneficial duodenal exclusion effects of bariatric surgery using an oral pill.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Oral gut-targeted polymer therapeutics (polymer-based drugs)
Industry: Biotech

Drug pipeline

1 asset

GLY-200

Beyond the preview

Go deeper on Glyscend Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glyscend Therapeutics.

Explore the full profile